| scholarly article | Q13442814 |
| P356 | DOI | 10.4161/HV.4746 |
| P698 | PubMed publication ID | 17938573 |
| P50 | author | Myron M. Levine | Q29564379 |
| Marcela F. Pasetti | Q56380831 | ||
| James P Nataro | Q61771354 | ||
| Karen L Kotloff | Q63214788 | ||
| P2093 | author name string | Marcelo B Sztein | |
| Sofie Livio | |||
| William C Blackwelder | |||
| Eileen M Barry | |||
| Jakub K Simon | |||
| Stacey L Wooden | |||
| Wendy Picking | |||
| P433 | issue | 6 | |
| P921 | main subject | Shigella flexneri | Q1644417 |
| P304 | page(s) | 268-275 | |
| P577 | publication date | 2007-07-15 | |
| P1433 | published in | Hum Vaccin | Q15755183 |
| P1476 | title | Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | |
| P478 | volume | 3 |
| Q57929967 | A Novel Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge |
| Q33801151 | A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection |
| Q91644990 | A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice |
| Q33557714 | A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors |
| Q84573053 | A new multiplex PCR for differential identification of Shigella flexneri and Shigella sonnei and detection of Shigella virulence determinants |
| Q37044185 | Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues |
| Q38284501 | An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children |
| Q40126474 | An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype. |
| Q37668395 | An update on vaccines against Shigella |
| Q35805439 | Broadly protective Shigella vaccine based on type III secretion apparatus proteins |
| Q30299919 | Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates |
| Q34394744 | Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity |
| Q38776163 | Characterization of a multicomponent live, attenuated Shigella flexneri vaccine |
| Q37276296 | Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes |
| Q34482917 | Chromosomal and plasmid-encoded factors of Shigella flexneri induce secretogenic activity ex vivo |
| Q37458618 | Effect of wild-type Shigella species and attenuated Shigella vaccine candidates on small intestinal barrier function, antigen trafficking, and cytokine release |
| Q30443288 | Enteric infections, diarrhea, and their impact on function and development |
| Q57068847 | Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella |
| Q37032264 | Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. |
| Q37633069 | Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study |
| Q34068059 | Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans |
| Q42554197 | Highlights of the 8th International Conference on Vaccines for Enteric Diseases: the Scottish Encounter To Defeat Diarrheal Diseases |
| Q28972559 | Immunology of Gut Mucosal Vaccines |
| Q35598035 | Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit |
| Q52336351 | Over-expression of O-polysaccharide chain length regulators in Gram-negative bacteria using the Wzx/Wzy-dependent pathway enhances production of defined modal length O polysaccharide polymers for use as haptens in glycoconjugate vaccines. |
| Q37105553 | Progress and pitfalls in Shigella vaccine research |
| Q92968346 | Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development |
| Q37477191 | Shigella Vaccine Development: Finding the Path of Least Resistance |
| Q39610195 | Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells |
| Q34935297 | Shigella flexneri 3a outer membrane protein C epitope is recognized by human umbilical cord sera and associated with protective activity |
| Q34202171 | Shigella isolates from the global enteric multicenter study inform vaccine development |
| Q56383780 | Shigellosis |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q52657631 | T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans. |
| Q39362868 | The synthesis of OspD3 (ShET2) in Shigella flexneri is independent of OspC1. |
| Q36898558 | Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors |
| Q33578045 | Vaccines against human diarrheal pathogens: current status and perspectives |
Search more.